IL18

Across TCGA pan-cancer cohorts, IL18 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IL18 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher IL18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL18 expression acts as an unfavorable survival marker.

THYM and PRAD are the cancer types where IL18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

IL18–THYM (OS)

Open the THYM breakdown →